For Immediate Release
Chicago, IL – March 28, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Roche Holding AG RHHBY, Thermo Fisher Scientific Inc. TMO, Mitsubishi UFJ Financial Group, Inc. MUFG and Synopsys, Inc. SNPS.
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Berkshire Hathaway, Roche and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Roche Holding AG and Thermo Fisher Scientific Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Berkshire Hathaway have modestly outperformed the Zacks Insurance - Property and Casualty industry over the past six months (+9.9% vs. +9.0%). The company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions. A strong cash position supports earnings-accretive bolt-on buyouts and indicates the financial flexibility.
Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
(You can read the full research report on Berkshire Hathaway here >>>)
Shares of Roche have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-29.4% vs. +2.4%). The company’s performance has been average of late as the demand for COVID-19 products declined significantly, even though the diagnostics base business and newer drugs, namely Hemlibra (hemophilia), Ocrevus (multiple sclerosis), Evrysdi (spinal muscular atrophy) and Tecentriq (cancer), maintained momentum.
Sales of Actemra/RoActemra and Ronapreve (COVID-19) are declining with the pandemic weakening in several countries since last year. However, 2023 is also expected to be a challenging year for the company due to the expected sharp decline in sales of COVID-19 products of roughly CHF 5 billion.
Nevertheless, the uptake of the new eye drug, Vabysmo, was outstanding. The Diagnostics business also remained stable in terms of the growth of its routine business.
(You can read the full research report on Roche here >>>)
Shares of Thermo Fisher Scientific have gained +7.8% over the past six months against the Zacks Medical - Instruments industry’s gain of +12.7%. The company’s robust year-over-year revenue growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.
During the fourth quarter, the company opened a new bioanalytical lab in Richmond, VA, to support its clinical research business. The integration of PPD is largely complete and drove strong returns for the shareholders with outstanding execution and business performance throughout the year.
However, revenues within Europe declined in the low teens. The same in Asia Pacific fell in the mid-single digits, while China registered a decline in the mid-single digits. Revenues in the rest of the world declined in high-single digits.
(You can read the full research report on Thermo Fisher Scientific here >>>)
Other noteworthy reports we are featuring today include Mitsubishi UFJ Financial Group, Inc. and Synopsys, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report